Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | HLX07 |
Synonyms | |
Therapy Description |
HLX07 is a humanized monoclonal antibody directed against EGFR, which was demonstarted to have increased affinty for Egfr as compared to cetuximab (JCO.2017.35.15_suppl.e14078). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HLX07 | HLX-07|HLX 07|Pimurutamab | EGFR Antibody 31 | HLX07 (Pimurutamab) is a humanized monoclonal antibody directed against EGFR, which was demonstrated to have increased affinity for Egfr as compared to cetuximab (JCO.2017.35.15_suppl.e14078). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02648490 | Phase I | Acetaminophen + Dexamethasone + Diphenhydramine + Ondansetron HLX07 | An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers | Completed | USA | 1 |